ArticlePlastic and reconstructive surgery. Global open2026
Comparing Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) and Targeted Approaches for OnabotulinumtoxinA in Chronic Migraine Treatment.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial.Aesthetic plastic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: OnabotulinumtoxinA is a Food and Drug Administration-approved treatment for chronic migraine prophylaxis. The standard injection paradigm is derived from the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials, which use fixed injection sites and do not account for peripheral nerve trigger zones implicated in migraine pathogenesis. Anatomically targeted injection strategies directed at these trigger sites have shown promise, but direct comparative evaluation with PREEMPT-based approaches remains limited. Methods: A systematic review and meta-analysis was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Embase and PubMed were searched for studies evaluating onabotulinumtoxinA administered using either PREEMPT or anatomically targeted injection techniques in patients with chronic migraine. Eligible studies reported outcomes including headache days per month, migraine headache index, or symptom elimination rates. Independent Results: Fifteen studies met inclusion criteria, including 13 PREEMPT-based studies (n = 1339) and 2 targeted injection studies (n = 48). Both strategies significantly reduced monthly headache frequency. In the PREEMPT cohort, headache days decreased from 23.3 ± 6.7 to 11.9 ± 7.9 per month ( Conclusions: Both PREEMPT and targeted onabotulinumtoxinA injections reduce migraine burden. Targeted treatment may offer advantages such as individualized therapy, lower toxin requirements, and fewer complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.